Openbookopenbook
Equity
CNTMF
+0.0 · +0.00%
USD · OTCQB

Cansortium Inc(CNTMF) Stock Analysis | Healthcare

USD --+0.00%
Reward60Moderate
Risk67Medium-High
75%Data
Thin -55% profit margin
Value Trap
Market Cap:25.49M
ⓘ
Reward Rating
60
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
67
Medium-High
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CNTMF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Cansortium Inc?

, through its subsidiaries, cultivates, manufactures processes, distributes, and sells medical cannabis products for medical and adult-use markets in Florida, New York, Pennsylvania, and Texas.

AI Brief Pro

The brief on Cansortium Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Cansortium Inc?

, through its subsidiaries, cultivates, manufactures processes, distributes, and sells medical cannabis products for medical and adult-use markets in Florida, New York, Pennsylvania, and Texas. The company's medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, edibles, and other accessories under the Fluent brand name. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 25.49M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

TXMDNano Cap / 25.6M market cap
TherapeuticsMD Inc
Compare
LEEEFNano Cap / 25.6M market cap
Leef Brands Inc.
Compare
LUFFFNano Cap / 24.8M market cap
Luff Enterprises Ltd
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap25.49M
P/E RatioN/A
Dividend YieldN/A
Beta0.827
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.